Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 243 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Karagiannis, Asterios [Clear All Filters]
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis..
J Clin Endocrinol Metab. 94(8), 2692-701.
(2009). The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings..
Arch Med Sci. 8(1), 6-10.
(2012). Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?.
Expert Opin Investig Drugs. 17(4), 445-9.
(2008). Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview..
Curr Vasc Pharmacol. 12(4), 627-41.
(2014). Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review..
Angiology. 65(4), 284-93.
(2014). Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients..
Curr Med Res Opin. 29(7), 791-2.
(2013). Cardiovascular Risk in Middle East Populations: A Call to Action..
Angiology. 66(9), 801-2.
(2015). Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update..
World J Gastroenterol. 21(22), 6820-34.
(2015). Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?.
Angiology. 60(1), 74-81.
(2009). Carbon dioxide balneotherapy and cardiovascular disease..
Int J Biometeorol. 55(5), 657-63.
(2011). Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia..
Curr Pharm Des. 24(46), 5542-5547.
(2018). Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis..
Metab Syndr Relat Disord. 8(6), 523-9.
(2010). Blood pressure and cardiovascular outcomes: a closer look..
Lancet. 389(10076), 1295-1296.
(2017). The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia..
Curr Med Chem. 27(39), 6682-6702.
(2020). Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention..
Curr Med Res Opin. 30(1), 55.
(2014). Atorvastatin: safety and tolerability..
Expert Opin Drug Saf. 9(4), 667-74.
(2010). Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients..
Lipids. 42(11), 999-1009.
(2007). Atherosclerotic renal artery stenosis: medical therapy alone or in combination with revascularization?.
Angiology. 60(4), 397-402.
(2009). Atherosclerotic renal artery stenosis: an update on diagnosis and management..
Curr Vasc Pharmacol. 9(4), 465-70.
(2011). Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?.
Curr Pharm Des. 13(2), 229-39.
(2007). Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort..
Angiology. 58(6), 689-97.
(2007). Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study..
Curr Med Res Opin. 27(8), 1659-68.
(2011). Arterial stiffness correlates with progressive nailfold capillary microscopic changes in systemic sclerosis: results from a cross-sectional study..
Arthritis Res Ther. 21(1), 253.
(2019). Arterial Stiffness and Emerging Biomarkers: Still a Long Journey to Go..
Angiology. 66(10), 901-3.
(2015). Arterial adaptations in athletes of dynamic and static sports disciplines - a pilot study..
Clin Physiol Funct Imaging. 39(3), 183-191.
(2019).